Alector Enters License Agreement with Genentech and Receives $100 Million Upfront Payment

Filing content

Alector entered into a license agreement with Genentech, receiving a $100 million upfront payment with potential for up to $1.17 billion in milestones and royalties, and also signed a separate license agreement with Spur Therapeutics.